These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25343308)

  • 1. Successful Treatment of Severe Right-Sided Heart Failure Due to Postoperative Constrictive Pericarditis With Tolvaptan.
    Kanaya M; Matsushita K; Inami T; Yamasaki S; Mizumi S; Minamishima T; Goda A; Ueda A; Sakata K; Satoh T; Yoshino H
    Am J Ther; 2016; 23(1):e264-7. PubMed ID: 25343308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preoperative Use of Tolvaptan in a Patient with Constrictive Pericarditis].
    Kawatsu S; Takahara S; Sakatsume K; Kanda K; Suzuki T; Katahira S; Fujiwara H; Adachi O; Akiyama M; Kumagai K; Kawamoto S; Saiki Y
    Kyobu Geka; 2016 Feb; 69(2):121-5. PubMed ID: 27075153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
    Imamura T; Kinugawa K
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure.
    Matsukawa R; Kubota T; Okabe M; Yamamoto Y
    Heart Vessels; 2016 Oct; 31(10):1650-8. PubMed ID: 26676672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice.
    Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience.
    Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629
    [No Abstract]   [Full Text] [Related]  

  • 8. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study.
    Okabe T; Yakushiji T; Igawa W; Ono M; Kido T; Ebara S; Yamashita K; Yamamoto MH; Saito S; Hoshimoto K; Amemiya K; Isomura N; Araki H; Ochiai M
    Cardiovasc Ther; 2015 Oct; 33(5):275-81. PubMed ID: 26122275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Chronic Use of Tolvaptan in Patients with Heart Failure Undergoing Peritoneal Dialysis.
    Mori T; Kurasawa N; Ohsaki Y; Koizumi K; Sato S; Oba-Yabana I; Shimada S; Sato E; Naganuma E; Tsuchikawa M; Ito S
    Adv Perit Dial; 2016; 32():39-45. PubMed ID: 28988588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tolvaptan on congestive heart failure complicated with chylothorax in a neonate.
    Sato N; Sugiura T; Nagasaki R; Suzuki K; Ito K; Kato T; Inukai S; Saitoh S
    Pediatr Int; 2015 Oct; 57(5):1020-2. PubMed ID: 26508187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin antagonists in heart failure.
    Golestaneh L; Talreja A; Le Jemtel TH
    Curr Heart Fail Rep; 2004 Dec; 1(4):190-6. PubMed ID: 16036044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study).
    Kinugawa K; Inomata T; Sato N; Yasuda M; Shimakawa T; Bando K; Mizuguchi K
    Int Heart J; 2015; 56(2):137-43. PubMed ID: 25740389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel diuretic strategies for the treatment of heart failure in Japan.
    Dohi K; Ito M
    Circ J; 2014; 78(8):1816-23. PubMed ID: 25008484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of tolvaptan for postoperative heart failure in a patient with combined valvular disease and pulmonary hypertension].
    Kondo T; Hoshino J; Fukada Y; Hirota M; Takahashi Y; Isomura T
    Kyobu Geka; 2014 Feb; 67(2):117-20. PubMed ID: 24743480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M; Hori M; Izumi T; Fukunami M;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension.
    Tamura Y; Kimura M; Takei M; Ono T; Kuwana M; Satoh T; Fukuda K; Humbert M
    Eur Respir J; 2015 Jul; 46(1):283-6. PubMed ID: 25929949
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).
    Higashi K; Murakami T; Ishikawa Y; Itoi T; Ohuchi H; Kodama Y; Honda T; Masutani S; Yamazawa H; Senzaki H; Ishikawa S
    Int J Cardiol; 2016 Feb; 205():37-42. PubMed ID: 26710331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure.
    Matsukawa R; Kubota T; Okabe M; Yamamoto Y; Meno H
    Heart Vessels; 2018 Feb; 33(2):145-154. PubMed ID: 28815407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
    Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
    Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.